{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:53:07Z","timestamp":1779112387210,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2110,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Third Military Medical University Clinic and Science Great Fund","award":["2101XLC03"],"award-info":[{"award-number":["2101XLC03"]}]},{"name":"Chongqing Postgraduate Education","award":["yjg123114"],"award-info":[{"award-number":["yjg123114"]}]},{"name":"National Natural Science Fund","award":["NSFC30971066"],"award-info":[{"award-number":["NSFC30971066"]}]},{"name":"National Natural Science Fund","award":["NSFC81270605"],"award-info":[{"award-number":["NSFC81270605"]}]},{"name":"Chongqing Natural Science Fund","award":["CSTC2008BA5001"],"award-info":[{"award-number":["CSTC2008BA5001"]}]},{"name":"Third Military Medical University Education"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1093\/annonc\/mdt566","type":"journal-article","created":{"date-parts":[[2014,1,29]],"date-time":"2014-01-29T10:26:26Z","timestamp":1390991186000},"page":"455-461","source":"Crossref","is-referenced-by-count":31,"title":["Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials"],"prefix":"10.1016","volume":"25","author":[{"given":"X.","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.N.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.B.","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.P.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt566_bb0010","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt566_bb0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ajh.23404","article-title":"Acute myeloid leukemia: 2013 update on risk-stratification and management","volume":"88","author":"Estey","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdt566_bb0020","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/CCO.0b013e328358f62d","article-title":"Current treatment of acute myeloid leukemia","volume":"24","author":"Roboz","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"10.1093\/annonc\/mdt566_bb0025","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1182\/blood-2013-03-490482","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug","volume":"121","author":"Rowe","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt566_bb0030","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2741\/4181","article-title":"Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin","volume":"18","author":"Cowan","year":"2013","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1093\/annonc\/mdt566_bb0035","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt566_bb0040","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdt566_bb0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt566_bb0050","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt566_bb0055","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt566_bb0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2012.229","article-title":"The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison","volume":"27","author":"Burnett","year":"2013","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdt566_bb0065","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1093\/annonc\/mdt566_bb0070","unstructured":"Centre for Drug Evaluation and Research, USA Food and Drug AdministrationGuidance for industry\u2014E12A: Principles for Clinical Evaluation of New Antihypertensive Drugs; http:\/\/www.fda.gov\/downloads\/RegulatoryInformation\/Guidances\/ucm129462.pdf (17 November 2013, date last accessed)"},{"key":"10.1093\/annonc\/mdt566_bb0075","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00277-013-1780-7","article-title":"De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened \u2018GO question","volume":"92","author":"Clavio","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdt566_bb0080","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.clml.2012.05.007","article-title":"High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk","volume":"12","author":"Tavor","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1093\/annonc\/mdt566_bb0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/1758834009355164","article-title":"Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management","volume":"2","author":"Stein","year":"2010","journal-title":"Ther Adv Med Oncol"},{"key":"10.1093\/annonc\/mdt566_bb0090","first-page":"65","article-title":"Dietetic management in gastrointestinal complications from antimalignant chemotherapy","volume":"27","author":"Calixto-Lima","year":"2012","journal-title":"Nutr Hosp"},{"key":"10.1093\/annonc\/mdt566_bb0095","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/j.leukres.2011.01.025","article-title":"Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes?","volume":"35","author":"Maniecki","year":"2011","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdt566_bb0100","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/jnci\/djs259","article-title":"Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review","volume":"104","author":"P\u00e9ron","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdt566_bb0105","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/humupd\/dmq043","article-title":"Individual patient data meta-analysis: a promising approach for evidence synthesis in reproductive medicine","volume":"16","author":"Broeze","year":"2010","journal-title":"Hum Reprod Update"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419364798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419364798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/2\/455\/16699770\/mdt566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:36:37Z","timestamp":1624505797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419364798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0923753419364798"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt566","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718258088.793499758","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}